Behavioral
Comprehensive Pain Management Specialists
Comprehensive Pain Management Specialists was paid $5.27M by Medicaid between Jan 2018 and Nov 2024, across 74 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoCOMPREHENSIVE PAIN MANAGEMENT SPECIALISTS
AKRON, OH 44312
AKRON, OH 44312
33aNPI1508007444assigned 03/23/2009
33bProvider typeClinical Social Worker
28Total paid$5.27M
24GClaims317,538
24DCodes billed74
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Social Worker providers in Ohio
Rank by total paid#8 of 347
Median peer was paid$29K
This provider vs. median184×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 115,278 | $1.16M | |
| 2019 | 97,026 | $1.12M | |
| 2020 | 49,046 | $807K | |
| 2021 | 18,467 | $685K | |
| 2022 | 15,078 | $553K | |
| 2023 | 12,845 | $540K | |
| 2024incomplete | 9,798 | $413K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 36,603 | 34,049 | $1.39M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 44,760 | 41,264 | $1.09M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 9.1% | 5,174 | 4,913 | $478K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 6,762 | 2,889 | $142K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.3% | 1,809 | 1,726 | $122K |
| 80346 | 2.3% | 7,642 | 7,538 | $119K | |
| 80361 | 1.9% | 7,645 | 7,537 | $99K | |
| 80364 | 1.6% | 6,597 | 6,504 | $83K | |
| 83992 | 1.5% | 7,639 | 7,534 | $78K | |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 1.5% | 1,325 | 852 | $78K |
| 80373 | 1.5% | 7,642 | 7,536 | $77K | |
| 80372 | 1.4% | 7,641 | 7,536 | $76K |
62 more codes
| 80357 | 1.4% | 7,641 | $76K | |
| 80366 | 1.4% | 7,230 | $71K | |
| 80355 | 1.3% | 7,233 | $71K | |
| 80368 | 1.3% | 6,910 | $70K | |
| 80369 | 1.3% | 6,910 | $68K | |
| 80339 | 1.3% | 6,672 | $66K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.2% | 1,320 | $65K |
| 80354 | 1.1% | 7,647 | $57K | |
| 80348 | 1.1% | 7,650 | $56K | |
| 80356 | 1.1% | 7,646 | $56K | |
| 80353 | 1.0% | 7,645 | $55K | |
| 80324 | 1.0% | 7,647 | $55K | |
| 80358 | 1.0% | 7,651 | $55K | |
| 80349 | 1.0% | 7,640 | $55K | |
| 80359 | 1.0% | 7,641 | $55K | |
| 80305 | <1% | 7,522 | $47K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 590 | $45K |
| 20611 | <1% | 941 | $45K | |
| E0730 | Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation | <1% | 493 | $37K |
| 80332 | <1% | 3,651 | $36K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,914 | $36K |
| 80345 | <1% | 3,255 | $25K | |
| 80350 | <1% | 3,255 | $25K | |
| 20553 | <1% | 785 | $25K | |
| 97161 | <1% | 527 | $24K | |
| 90838 | <1% | 437 | $21K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 300 | $20K |
| 27096 | <1% | 212 | $20K | |
| 80362 | <1% | 988 | $19K | |
| 62323 | <1% | 284 | $18K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 734 | $17K |
| 80365 | <1% | 988 | $10K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,503 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 161 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 503 | $6K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 93 | $4K |
| 80338 | <1% | 385 | $4K | |
| 80336 | <1% | 384 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 129 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 504 | $1K |
| 99442 | <1% | 223 | $1K | |
| A4595 | Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes) | <1% | 50 | $954.33 |
| 80320 | <1% | 72 | $954.24 | |
| 64493 | <1% | 13 | $730.77 | |
| 20610 | <1% | 27 | $612.36 | |
| 64494 | <1% | 13 | $396.24 | |
| J3490 | Unclassified drugs | <1% | 195 | $163.22 |
| 80335 | <1% | 385 | $21.75 | |
| S9452 | Nutrition classes, non-physician provider, per session | <1% | 2,721 | $13.12 |
| 99406 | <1% | 48 | $0.11 | |
| S9451 | Exercise classes, non-physician provider, per session | 0% | 3,810 | $0.00 |
| 1036F | 0% | 4,315 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 1,554 | $0.00 |
| G8959 | Clinician treating major depressive disorder communicates to clinician treating comorbid condition | 0% | 35 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 29 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 5,366 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 10,522 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 2,317 | $0.00 |
| 4004F | 0% | 2,746 | $0.00 | |
| S9449 | Weight management classes, non-physician provider, per session | 0% | 2,708 | $0.00 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 3,489 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLABABIDI, TONY (OWNER/MEDICAL DIRECTOR)